Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tracy Hall

Sports Medicine Greenville, IL Doctor of Osteopathy

NPI 1659366102 CMS profile 29187

201 Health Care Dr, Greenville, IL 62246

Open in the dashboard

General payments

$7,446

423 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tracy Hall of Greenville, IL is reported in the CMS Open Payments database as having received $7,446 across 423 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,311 70
2024 General $1,488 89
2023 General $1,102 72
2022 General $775 49
2021 General $874 66
2020 General $1,310 28
2019 General $587 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tracy Hall
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Tracy Hall were reported at $1,311. Among 1,257 Sports Medicine profiles paid that year, the median was $114 and the middle half received between $39 and $293.

Show as a table
Year Tracy Hall Sports Medicine median Middle half National median
2019 $587 $119 $35–$362 $163
2020 $1,310 $77 $24–$275 $114
2021 $874 $104 $28–$340 $132
2022 $775 $94 $31–$272 $149
2023 $1,102 $91 $34–$271 $160
2024 $1,488 $126 $38–$294 $164
2025 $1,311 $114 $39–$293 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,328 76 payments
  2. AbbVie, Inc. $1,252 97 payments
  3. Allergan Inc. $925 4 payments
  4. Lilly USA, LLC $717 39 payments
  5. Novo Nordisk Inc $621 47 payments
  6. GlaxoSmithKline, LLC. $326 20 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $283 12 payments
  8. Pfizer Inc. $230 24 payments
  9. Sanofi-Aventis U.S. LLC $202 12 payments
  10. ITI, Inc. $176 8 payments
  11. Other $1,386 84 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,676 422 payments
  2. Consulting Fee $770 1 payment
Products named General payments · program years 2019–2025
  1. BOTOX $770 1 payment
  2. BREZTRI $769 38 payments
  3. FARXIGA $605 31 payments
  4. MOUNJARO $521 27 payments
  5. VRAYLAR $519 40 payments
  6. QULIPTA $439 36 payments
  7. Ozempic $406 31 payments
  8. RYBELSUS $392 30 payments
  9. TRULICITY $239 13 payments
  10. TRELEGY ELLIPTA $229 14 payments
  11. Other $4,490 292 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 125 drugs

Part D claims

6,374

Median for Family Medicine: 130

Drug cost

$586,693

Median for Family Medicine: $5,773

Branded share of claims

19.5%

Median for Family Medicine: 16%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 111 $115,465
Ozempic Semaglutide Brand 67 $110,473
Mounjaro Tirzepatide Brand 41 $78,834
Jardiance Empagliflozin Brand 44 $53,557
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 24 $22,444
Hysingla Er Hydrocodone Bitartrate Brand 12 $22,328
Xarelto Rivaroxaban Brand 31 $21,776
Januvia Sitagliptin Phosphate Brand 22 $21,524
Breo Ellipta Fluticasone/Vilanterol Brand 34 $16,825
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 12 $13,174

The 10 drugs with the highest cost, of 125 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 699 Part D prescribers listed as Family Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $240
$240 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $152
$152 12 —
MOUNJARO
  • Lilly USA, LLC $146
$146 41 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $105
$105 — —
CAPLYTA
  • ITI, Inc. $83
$83 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

423 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record